EC Gynaecology

Vulvar melanoma (VM) is an uncommon aggressive gynecological malignancy that accounts 2-10% of all vulvar tumors [1]. An early, accurate diagnosis is essential in reaching appropriate treatment decisions, although this can be difficult as their clinical presentation may be variable especially in amelanotic lesions such as in our case. Advanced stages of presentation affect long-term survival and the quality of life. Surgical resection with adequate free margins is the mainstay of treatment for localized disease, as to date there is no clear consensus regarding therapeutic treatment. Histopathological examination and further immunohistochemistry studies are essential in diagnosis and staging.

We report a case of a 48-year-old woman presenting with advanced stage primary vulvar melanoma and review the literature regarding the current management approach and updates of this rare gynecological cancer.

Keywords: Vulvar Melanoma; Gynecological Malignancy; Malignant Melanoma; Melanoma Prognosis

1. Mihajlovic M., et al. “Primary mucosal melanoma”. International Journal of Clinical and Experimental Pathology 8 (2012): 739-753.
2. Falcicchio G., et al. “Vulvar Malignant Melanoma: A Narrative Review”. Cancers 14 (2022): 5217.
3. Coit DG., et al. “Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology”. Chemotherapy-Induced Peripheral Neurotoxicity in Cancer 14 (2016): 450-473.
4. Shi K., et al. “Distinct Genomic Features in a Retrospective Cohort of Mucosal, Acral and Vulvovaginal Melanomas”. Journal of the American Academy of Dermatology (2019).
5. Ditto A., et al. “Surgical Management and Prognostic Factors of Vulvovaginal Melanoma”. Journal of Lower Genital Tract Disease 20 (2016): e24-e29.
6. Gupta D., et al. “Vaginal melanoma: a clinicopathologic and immunohistochemical study of 26 cases”. The American Journal of Surgical Pathology11 (2002): 1450-1457.
7. Smith HG., et al. “Ano-uro-genital mucosal melanoma UK national guidelines”. European Journal of Cancer 135 (2020): 22-30.
8. Wylomanski S., et al. “BRAF mutations might be more common than supposed in vulvar melanomas”. Experimental Dermatology 27 (2018): 210-213.
9. Dias-Santagata D., et al. “KIT mutations and CD117 overexpression are markers of better progression-free survival in vulvar melanomas”. British Journal of Dermatology 177 (2017): 1376-1384.
10. Kim G., et al. “FDA approval summary: Vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation”. Clinical Cancer Research 20 (2014): 4994-5000.
11. Saleh B., et al. “Frequent PD-L1 Expression in Malignant Melanomas of the Vulva”. International Journal of Gynecological Pathology 37 (2018): 477-481.
12. Wohlmuth C and Wohlmuth-Wieser I. “Vulvar Melanoma: Molecular Characteristics, Diagnosis, Surgical Management, and Medical Treatment”. American Journal of Clinical Dermatology5 (2021): 639-651.
13. Iacoponi S., et al. “Prognostic Factors of Recurrence and Survival in Vulvar Melanoma: Subgroup Analysis of the VULvar CANcer Study”. The International Journal of Gynecological Cancer 26 (2016): 1307-1312.
14. Janco JM., et al. “Vulvar and vaginal melanoma: Case series and review of current management options including neoadjuvant chemotherapy”. Gynecologic Oncology 129 (2013): 533-537.
15. Verschraegen CF., et al. “Vulvar melanoma at the M. D. Anderson Cancer Center: 25 years later”. The International Journal of Gynecological Cancer 11 (2001): 359-364.
16. Albert A., et al. “Vulvar melanoma: An analysis of prognostic factors and treatment patterns”. Journal of Gynecologic Oncology 31 (2020): e66.
17. Murzaku EC., et al. “Vulvar nevi, melanosis, and melanoma: An epidemiologic, clinical, and histopathologic review”. Journal of the American Academy of Dermatology 71 (2014): 1241-1249.
18. Sánchez-Prieto M., et al. “Surgical Management of Vulvar Melanoma: A Case Series”. Case Reports in Oncology (2021): 1144-1151.
19. Preti M and Querleu D. “Vulvar Cancer: Facing a Rare Disease”. Cancers 14 (2022): 1581.
20. Aulmann S., et al. “Comparison of molecular abnormalities in vulvar and vaginal melanomas”. Modern Pathology 27 (2014): 1386-1393.
21. Sugiyama VE., et al. “Vulvar melanoma: A multivariable analysis of 644 patients”. Obstetrics and Gynecology 110 (2007): 296-301.
22. Mehra T., et al. “Primary localization and tumor thickness as prognostic factors of survival in patients with mucosal melanoma”. PLoS ONE 9 (2014): e112535.
23. Gadducci A., et al. “Melanoma of the lower genital tract: Prognostic factors and treatment modalities”. Gynecologic Oncology 150 (2018): 180-189.
24. Sinasac SE., et al. “Melanoma of the Vulva and Vagina: Surgical Management and Outcomes Based on a Clinicopathologic Review of 68 Cases”. Journal of Obstetrics and Gynaecology Canada 41 (2019): 762-771.
25. Bainvoll L., et al. “Sentinel lymph node biopsy for vulvar melanoma: Trends in tumor stage-specific utilization”. American Journal of Obstetrics and Gynecology 226 (2022): 438-440.
26. Leitao MM Jr., et al. “Gynecologic Cancer Inter Group (GCIG) consensus review for vulvovaginal melanomas”. The International Journal of Gynecological Cancer9-3 (2014): S117-S122.
27. Irvin WP Jr., et al. “Malignant melanoma of the vagina and locoregional control: radical surgery revisited”. Gynecologic Oncology 3 (1998): 476-480.